Deep Dive: Page 12
Industry insights from our journalists
-
Innovation update: Advancing the standard of care in rheumatoid arthritis
This year’s ACR meeting highlighted new developments in rheumatoid arthritis (RA). We spoke to Dr. Terence Rooney, Medical Director of Lilly Bio-Medicines and Dr. Rory O’Connor, Senior Vice President and Head of Global Medical Affairs at Pfizer about JAK inhibition, innovation, and new treatment options for RA.
Nicole Gray • Nov. 19, 2015 -
Senators grilled Obama's nominee for FDA chief. Here's how he responded
The powerful Senate Health, Education, Labor, and Pensions Committee questioned Dr. Robert Califf on everything from his past ties to the pharmaceutical industry to how he'd tackle the major issues facing the Food and Drug Administration.
Sy Mukherjee and Ned Pagliarulo • Nov. 18, 2015 -
Liver Meeting '15 wrapup: Battling more hep C genotypes, shortening treatment regimens
The face of hepatitis treatment has transformed in the past two years. But drug makers aren't through reaching for even greater heights.
Sy Mukherjee • Nov. 18, 2015 -
Liver Meeting '15: AASLD calls out payers on HCV med coverage; WHO's plan to wipe out hep C & B by 2030
On the second-to-last day of the annual Liver Meeting, the World Health Organization plotted an ambitious plan for eliminating viral hepatitis, and several pharma companies continued to present data on new, next-gen drug combos.
Sy Mukherjee • Nov. 17, 2015 -
NEJM joins the fray in drug pricing debate as 2 thought leaders share divergent perspectives
Dr. William W. Chin and Dr. Peter Bach are experienced thought leaders with important positions in the biopharma and medical communities—and they have very different opinions about drug pricing and healthcare sustainability.
Nicole Gray • Nov. 16, 2015 -
3 charts that show how VC funding in life sciences reached all-time highs in Q3
PricewaterhouseCoopers has released its latest MoneyTree report, and it contains (mostly) great news for the life sciences in general and biotech in particular—including record early-stage investments by VCs.
Sy Mukherjee • Nov. 13, 2015 -
Outer space: The final frontier of biopharma R&D
Merck, Lilly, Novartis, and others are already carrying out drug discovery efforts on the International Space Station's (ISS) National Lab. Here's why the Center for the Advancement of Science in Space (CASIS) thinks others in the life sciences should take a bet on the cosmos.
Sy Mukherjee • Nov. 11, 2015 -
A huge untapped opportunity for pharma marketing: Social media engagement with doctors
A recent report from the Deloitte Center for Health Solutions highlights third-party health content providers' successful strategy for engaging physicians in an increasingly digital world, along with ideas for how pharma can increase its social media presence with docs.
Nicole Gray • Nov. 6, 2015 -
As generic drug savings reach all-time high, experts ponder biosims' long-term impact
U.S. generic drug savings reached a peak of $254 billion in 2014, but biosimilars were not part of the analysis. How will those figures look once biosims enter the equation?
Nicole Gray • Nov. 5, 2015 -
Hep C and long-term costs: Why safety is suddenly part of the value equation
We spoke with Brian Overstreet, President of Advera Health Analytics, about AbbVie's Viekira Pak’s safety signals and why safety will increasingly be seen as part of overall medication costs.
Nicole Gray • Oct. 30, 2015 -
Drug shortages & patent expiration: Authorized generics as more than a lifecycle strategy
We spoke with Dr. Cary Yonce, Vice President of General Therapeutics and Life Cycle Management at Sanofi, about the patient demand for generic Arava and the company's response to that demand 10 years after patent expiry.
Nicole Gray • Oct. 27, 2015 -
3 earnings beats and a miss: Examining Pfizer, Merck, Bristol-Myers, and Novartis' Q3
New immuno-oncology drugs boosted Merck and BMS while Pfizer benefited from strong vaccines unit sales (even while taking a hit from completion of its Hospira deal). Meanwhile, a fourth pharma giant, Novartis, missed expectations in part due to a $390 million kickback settlement.
Sy Mukherjee • Oct. 27, 2015 -
How Valeant tried to defend itself on Monday morning's investor call
In a carefully worded investor call and webcast, Valeant executives defended the company's accounting practices and relationship with specialty pharmacies, while refuting Citron Research's stunning allegations. But the question is whether that will assuage investors.
Sy Mukherjee • Oct. 26, 2015 -
What in the world is going on at Valeant? A guide to what we know so far
On Wednesday, a short seller-run research group lobbed allegations of shoddy accounting and business practices at the pharma giant, even dubbing it "the pharmaceutical Enron." The stock sank. Here's some background.
Sy Mukherjee • Oct. 22, 2015 -
A Boehringer SVP and BioSig's CEO dish on the 'heart' of innovation
BioPharma Dive spoke with Dr. Sabine Luik, Senior Vice President of Medicine & Regulatory Affairs at Boehringer Ingelheim and Greg Cash, CEO of BioSig Technologies, about different strategies for reducing the risk of stroke in patients with atrial fibrillation—and what makes their products innovative.
Nicole Gray • Oct. 20, 2015 -
Breast Cancer Awareness Month: A look at recent innovations in breast cancer
This month marks the 30th year of Breast Cancer Awareness Month (BCAM). In recognition of the milestone, here is a brief look at recent innovations in diagnosis, surgery, and medical treatment for the disease.
Nicole Gray • Oct. 16, 2015 -
Diabetes therapeutics: A hotbed of innovation and reservoir of pharma progress
The recent CV data on Jardiance is the latest breakthrough in diabetes therapeutics. We spoke with Boehringer Ingelheim's Dr. Thomas Seck; a treating physician; and a marketing specialist about what comes next.
Nicole Gray • Oct. 14, 2015 -
The 'best-performing' CEO in the world is a pharma chief
Novo Nordisk's Lars Sørensen took the top spot in the Harvard Business Review's annual ranking of corporate execs this year. So did a number of other biopharma and healthcare CEOs—but it's a very different set of players from last time around.
Sy Mukherjee • Oct. 14, 2015 -
An inside look at Lilly's NYC expansion & focus on cancer immunotherapy
We paid a visit to Lilly’s NYC hub to learn more about the firm's new status as the pharma company with the largest amount of lab space in the Big Apple and its fresh Breakthrough Therapy Designation for a metastatic breast cancer drug.
Nicole Gray • Oct. 9, 2015 -
An innovation challenge: Using pharma R&D as a tool for social change
We spoke with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, about how a new way of understanding certain diseases could not only treat symptoms, but quell stigma and help many patients sleep better.
Nicole Gray • Oct. 8, 2015 -
Chasing a ghost: Why is FDA guidance on biosim interchangeability taking so long?
We spoke with Dave Fox, former associate chief counsel for drugs at the FDA and a partner in Hogan Lovell’s Life Sciences practice in Washington, D.C., to gain insight into the evolution of the biosimilars industry in the U.S.
Nicole Gray • Oct. 2, 2015 -
10 top trends driving the biopharma industry today
From pricing controversies to the continued deluge of M&As, to put-up-or-shut-up moments for hotly anticipated drug candidates, here are 10 of the most important industry trends that biopharma professionals need to understand.
Sy Mukherjee • Oct. 1, 2015 -
Has the era of the super successful pharma sales rep really come to an end?
We spoke with James Crowley, author of the Accenture report “The Rebirth of the Pharmaceutical Sales Force,” to gain insights into why some pharma sales reps are actually doing better than ever.
Nicole Gray • Sept. 23, 2015 -
Is Martin Shkreli biopharma's unwitting whistleblower?
The outspoken Turing Pharma CEO's tactics haven't won him much love. But exorbitant price hikes aren't exactly rare in the contemporary life sciences sector—and now, those practices are in the public limelight.
Sy Mukherjee • Sept. 23, 2015 -
An update on first-ever US biosim Zarxio 2 weeks after its debut
We spoke with the senior director of biosimilars research at Decision Resources Group to get her assessment of the historic (by U.S. standards) Neupogen biosim—and to ask why it's not as discounted as some had expected.
Nicole Gray • Sept. 17, 2015
Previous
To find more content, use the "Topics" in the menu above.
